Skip to main content
SpringerLink
Log in

Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

In this study the efficacy of treatment of two cyclo-oxygenase inhibitors, ibuprofen (Ibu) and indomethacin (Indo), are compared in the immunotherapy of metastasis designed to reverse prostaglandin E2 (PGE2)mediated inactivation of interleukin-2 (IL-2)-dependent host killer cell lineages. These agents were tested either alone for the prevention of metastasis or in combination with IL-2 for the eradication of established metastasis. C3H/HeN mice were placed on chronic oral Ibu (CIbT; 200 and 600 ,μg/ml of water) or Indo (CIT; 10 μg/ml) 5 days after s.c. transplantation of 5 × 105 metastatic C3L5 mammary carcinoma for the prevention of spontaneous lung metastases. They showed intolerance to Indo at a dosage of 14 μg/ml, which was well tolerated by other mouse strains in previous studies, but tolerated the Ibu dosages used. Control and treated mice were killed on day 30 to score metastatic lung colonies, to evaluate killer activity in splenocytes against natural killer (NK)-sensitive YAC-1 lymphoma or NK-resistant C3L5 adenocarcinoma and 8911 lymphoma targets, and to phenotype the surface markers of killer cells. CIbT and CIT alone at the above dosage significantly reduced the number of lung colonies, retarded local tumor growth and restored NK activity of splenic killer cells expressing AGM-1+, Thy-1−, Lyt-2− phenotype. To treat established lung metastasis, mice bearing 15-day C3L5 transplants were given CIbT or CIT alone or in combination with two 4-day rounds (days 20–23, 31–34) of IL-2 (15 000 Cetus units, i.p. every 8 h) and were killed on day 35 to score lung colonies and characterize splenic killer cells. CIbT or CIT alone reduced the number of spontaneous lung metastases and restored anti-YAC-1 killer function of splenocytes with NK-like phenotype (AGM-1+, Thy-1−, Lyt-2−); some anti-C3L5 killer function was also generated in the high dose Ibu group and the killer cell showed AGM-1+, Thy-1+ and Lyt-2+ phenotype. Combined therapies with CIbT or CIT plus IL-2 were more effective in reducing metastases and promoting killer cell function, the best results being achieved with high dose Ibu + IL-2. All killer cells expressed AGM-1 and Thy-1. In addition, C3L5 killer cells also expressed Lyt-2, suggesting T-cell stimulation. PGE2 synthesis in the host was inhibited by at least 50% in mice subjected to CIbT or CIT. Thus, Ibu proved to be an excellent substitute for Indo in preventing metastasis and NK cell activation when given alone, and also in ameliorating established metastasis and activating lymphokine-activated killer cells when combined with IL-2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hanna, N. Review of evidence for role of NK cells in immunoprophylaxis of metastasis. In: Herberman, RB, Wiltrout, RH and Gorelik, E, eds. Immune Responses to Metastases, Vol. II, pp. 13–23. Boca Raton, FL: CRC Press, 1987.

    Google Scholar 

  2. Hanna, N. Role of natural killer cells in host defense against cancer metastasis. In: Nicolson, GL and Milas L, eds. Cancer Invasion and Metastasis: biologic and therapeutic aspects, pp. 309–319. New York: Raven Press, 1984.

    Google Scholar 

  3. Fidler, IJ. The generation of tumoricidal activity in macrophages for the treatment of established metastases. In: Nicolson, GL and Milas, L, eds. Cancer Invasion and Metastasis: biologic and therapeutic aspects, pp. 421–435. New York: Raven Press, 1984.

    Google Scholar 

  4. Lafreniere, R and Rosenberg, SA, 1985, Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant Interleukin-2. Cancer Research, 45, 3735–3741.

    Google Scholar 

  5. Rosenberg, SA, Mule, JJ, Spiess, PJ, Reichert, CM and Schwarz, SL, 1985, Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant Interleukin-2. Journal of Experimental Medicine, 161, 1169–1188.

    Google Scholar 

  6. Rolland, PH, Martin, PM, Jacquemier, J, Rolland, AM and Toga, M, 1980, Prostaglandin in human breast cancer: evidence suggesting an elevated prostaglan din production is a marker of high metastatic potential for neoplastic cells. Journal of the National Cancer Institute, 64, 1061–1070.

    Google Scholar 

  7. Horn, KV, Bockman, RS and Marnett, LJ, 1981, Prostaglandin and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins, 21, 833–864.

    Google Scholar 

  8. Fulton, AM, 1988, The role of eicosanoids in tumor metastasis. Prostaglandins, Leukotrienes and Essential Fatty Acids, 34, 229–237.

    Google Scholar 

  9. Goodwin, JS and Ceuppens, J, 1983, Regulation of the immune response by prostaglandins. Journal of Clinical Immunology, 3, 295–315.

    Google Scholar 

  10. Lala, PK and McKenzie, IFC, 1982, An analysis of T lymphocyte subsets in tumor-transplanted mice on the basis of Lyt antigenic markers and functions. Immunology, 47, 663–677

    Google Scholar 

  11. Pope, BL, 1985, Activation of suppressor T cells by low-molecular-weight factors secreted by spleen cells from tumor-bearing mice. Cellular Immunology, 93, 364–374.

    Google Scholar 

  12. Lala, PK, PGE2 mediated inactivation of potentially tumoricidal effector cells of the host during tumor development: relevance to metastasis and immuno therapy. In: Abraham, S, ed. Carcinogenesis and Dietary Fat, pp. 219–232. Nowell, MA: S. Martinus Nijhoff Publishers, 1989.

    Google Scholar 

  13. Parhar, RS and Lala, PK, 1985, Changes in the host killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity. Cellular Immunology, 93, 265–279.

    Google Scholar 

  14. Parhar, RS and Lala, PK, 1988, Prostaglandin E-2mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. Journal of Leukocyte Biology, 44, 474–484.

    Google Scholar 

  15. Fulton, AM and Levy, JG, 1981, The induction of nonspecific T suppressor lymphocytes by Prostaglandin E1. Cellular Immunology, 59, 54–60.

    Google Scholar 

  16. Rappaport, RS and Dodge, GR, 1982, Prostaglandin E inhibits the production of human Interleukin-2. Journal of Experimental Medicine, 155, 943–948.

    Google Scholar 

  17. Parhar, RS, Yagel, S and Lala, PK, 1989, PGE2-mediated immunosuppression by first trimester human decidual cells blocks activation of maternal leukocytes in the decidua with potential anti-trophoblast activity. Cellular Immunology, 120, 61–74.

    Google Scholar 

  18. Lala, PK, Kennedy, TG and Parhar, RS, 1988, Suppression of lymphocyte alloreactivity by early gestational human decidua: 11. Characterization of the suppressor mechanisms. Cellular Immunology, 116, 411–422.

    Google Scholar 

  19. Hefeneider, SH, Conlon, PJ, Henney, CS and Gillis, S, 1983, In vivo Interleukin-2 administration augments the generation of alloreactive cytolytic T lympho cytes and resident natural killer cells. Journal of Immunology, 130, 222–227.

    Google Scholar 

  20. Pace, JL, 1988, Synergistic interactions between IFN-α and IFN-τ in priming murine macrophages for tumor cell killing. Journal of Leukocyte Biology, 44, 514–520.

    Google Scholar 

  21. Brooks, CG and Henney, CS. Interleukin-2 and the regulation of natural killer activity of cultured cell populations. In: Gillis, S and Inman, FP, eds. Con tempory Topics in Molecular Immunology, Vol. 10, pp. 63–92. New York: Plenum, 1985.

    Google Scholar 

  22. Reem, GH and Yeh, N-H, 1984, Interleukin-2 regulates expression of its receptor and synthesis of τ-Interferon by human T lymphocytes. Science, 225, 429–430.

    Google Scholar 

  23. Samuelsson, B, Granstrom, E, Green, K, Hamberg, M and Hammarstrom, S, 1975, Prostaglandins. Annual Review of Biochemistry, 44, 669–695.

    Google Scholar 

  24. Lala, PK, Parhar, RS and Singh, P, 1986, Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cellular Immunology, 99, 108–118.

    Google Scholar 

  25. Nelson, JAS, Parhar, RS, Scodras, JM and Lala, PK, 1990, Down-regulation of macrophage I-A expression in tumor-bearing mice. Journal of Leukocyte Biology, 48, 394–402.

    Google Scholar 

  26. Lala, PK and Parhar, RS, 1988, Chronic indomethacin therapy combined with IL-2 cures primary mammary adenocarcinomas and their spontaneous lung metastases. Proceedings of the American Association for Cancer Research, 29, 405 (Abstract).

    Google Scholar 

  27. Parhar, RS and Lala, PK, 1987, Amelioration of B16F10 melanoma lung metastasis in mice by combination therapy with indomethacin and interleukin-2. Journal of Experimental Medicine, 165, 14–28.

    Google Scholar 

  28. Lala, PK and Parhar, RS, 1988, Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of Interleukin 2: characteristics of killer cells generated in situ. Cancer Research, 48, 1072–1079.

    Google Scholar 

  29. Parhar RS, Chambers AF and Lala PK, 1988, A comparison of the efficacy of indomethacin, IL-2, IFN-τ on their various combinations in the treatment of experimental lung metastasis. Proceedings of the 19th International Leukocyte Culture Conference, Banff, AL, 80 (Abstract).

  30. Lala, PK, Elkashab, M, Kerbel, RS and Parhar, RS, 1990, Cure of human melanoma lung metastases in nude mice with chronic Indomethacin therapy com bined with multiple rounds of IL-2: characteristics of killer cells generated in situ. International Journal of Immunology, 2, 1149–1158.

    Google Scholar 

  31. Parhar RS, Kerbel RS and Lala PK, 1989, Chronic indomethacin plus intermittent IL-2 therapy activates killer cells in situ and cures multi-organ human melanoma metastases in nude mice. Proceedings of the 7th International Congress of Immunology, Berlin, 759 (Abstract).

  32. Mertens, W, Bramwell, VHC and Lala, PK, 1991, Do Indomethacin (Indo) and Ranitidine (Rant) contribute significantly to responses in advanced melanoma patients treated with high-dose Interleukin-2? Proceedings of the American Society of Clinical Oncology, 10, 209 (Abstract).

    Google Scholar 

  33. Bramwell, VHC, Mertens, WC and Lala, PK, 1991, Continuous oral indomethacin (Indo) and Ranitidine (Rant) and continuous venous infusion Interleukin-2 (IL-2) in advanced renal carcinoma. Proceedings of the American Society of Clinical Oncology, 10, 171 (Abstract).

    Google Scholar 

  34. Brodt, P, Parhar, R, Sankar, P and Lala, PK, 1985, Studies on clonal heterogeneity in two spontaneously metastasizing mammary carcinomas of recent origin. International Journal of Cancer, 35, 265–273.

    Google Scholar 

  35. Mueller, RE, Ball, JK and Chan, FPH, 1989, Characterization of cell markers in type B retroviral-induced thymic lymphomas: II. Surface antigen phenotype, karyotype and proviral integration pattern in cultured lymphoma cells and cloned lines. Leukemia Research, 13, 561–571.

    Google Scholar 

  36. Boardman, PL and Hart, DF, 1967, Side effects of Indomethacin. Annals of the Rheumatic Diseases, 26, 127–132.

    Google Scholar 

  37. Fulton, AM and Levy, JG, 1980, Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin. International Journal of Cancer, 26, 669–673.

    Google Scholar 

  38. Lynch, NR, Castes, M, Astoin, M and Salomon, JC, 1978, Mechanism of inhibition of tumor growth by aspirin and Indomethacin. British Journal of Cancer, 38, 503–512.

    Google Scholar 

  39. Fulton, AM, 1987, Interactions of natural effector cells and prostaglandins in the control of metastasis. Journal of the National Cancer Institute, 78, 735–741.

    Google Scholar 

  40. Maca, RD, 1988, Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude and beige mice. Journal of Biological Response Modifiers, 7, 568–580.

    Google Scholar 

  41. Young, MR and Newby, M, 1986, Enhancement of Lewis lung carcinoma cell migration by Prostaglandin E2 produced by macrophages. Cancer Research, 46, 160–164.

    Google Scholar 

  42. Young, MR, Young, ME and Wepsic, HT, 1987, Effect of prostaglandin E2-producing nonmetastatic Lewis lung carcinoma cells on the migration of prostaglandin E2-responsive metastatic Lewis lung carcinoma cells. Cancer Research, 47, 3679–3683.

    Google Scholar 

  43. Fulton, AM, Hanchin, CM and Butler, WB, 1988, Heterogeneity of Prostaglandin E2 binding in murine mammary tumor cells differing in metastatic potential. Invasion and Metastasis, 8, 17–30.

    Google Scholar 

  44. Folkman, J and Klagsbrun, M, 1987, Angiogenic factors. Science, 236, 442–447.

    Google Scholar 

  45. Farrel, CL, Megyesi, J and Del Maestro, RF, 1988, Effect of Ibuprofen on tumor growth in C6 spheroid implantation glioma model. Journal of Neurosurgery, 68, 925–930.

    Google Scholar 

  46. Shu, S, Chou, T and Rosenberg, SA, 1987, Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. Journal of Immunology, 139, 295–304.

    Google Scholar 

  47. Favrot, M, Blay, JY, Combaret, V, Negrier, S and Philip, T, 1990, Correlation between clinical response and immunological modifications induced on PBL in vivo by IL-2 therapy. Proceedings of the American Association for Cancer Research, 31, 277 (Abstract).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anatomy, University of Western Ontario, London, Ontario, Canada

    Nelson K. S. Khoo, Francis P. H. Chan, Mary Nel Saarloos & Peeyush K. Lala

Authors
  1. Nelson K. S. Khoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francis P. H. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary Nel Saarloos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peeyush K. Lala
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khoo, N.K.S., Chan, F.P.H., Saarloos, M.N. et al. Immunotherapy of mammary adenocarcinoma metastases in C3H/HeN mice with chronic administration of cyclo-oxygenase inhibitors alone or in combination with IL-2. Clin Exp Metast 10, 239–252 (1992). https://doi.org/10.1007/BF00133559

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00133559

Keywords

Search

Navigation